TheraRadar
← Back
Data updated: Jul 17, 2026

ASPEN

Specialty

ASPEN is a specialty pharmaceutical company focused on Neurology.

1999
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

ASPEN's Key Drugs

ASPEN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ASPEN's Recent FDA Approvals

New NDA/BLA approvals for ASPEN over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ASPEN's Therapeutic Areas

ASPEN's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
0 drugs Phase 1: 1

ASPEN's Top Competitors

ASPEN's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ASPEN Pipeline Snapshot

ASPEN has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling